Category Archives: CROI

via Eurekalert.org A change in the formulation of tenofovir gel, an anti-HIV gel developed for vaginal use, may make it safer to use in the rectum, suggests a study published online this week in the Journal of Antimicrobial Chemotherapy. In laboratory tests of rectal tissue, researchers from the Microbicide Trials Network (MTN) found that the reformulated gel Read More >>

via AidsMap.com, by Gus Cairns An meta-analysis of HIV-negative gay men’s sexual behaviour and HIV incidence rate in four HIV prevention studies, presented earlier this month at the 19th Conference on Retroviruses and Opportunistic Infections (CROI), has found that attempting to ‘serosort’ by restricting unprotected sex to partners known to be HIV negative does have efficacy as Read More >>

via The New York Times, by Donald G. McNeil Jr. The failure of a daily pill to protect healthy African women against AIDS may not have been the pill’s fault but the women’s reluctance to take it, scientists at an important AIDS conference in Seattle were told this week. Last April, a promising trial of “pre-exposure prophylaxis” Read More >>

via Nature News, by Erika Check Hayden Preventing the spread of HIV used to mean testing people for infection and encouraging them to practise safe sex. Increasingly, it also means prescribing drugs, as studies show that giving infected people or their uninfected partners antiretroviral drugs as soon as an infection is diagnosed can help to check the Read More >>

via AidsMap.com, by Gus Cairns The first trial in humans of an injectable, once-a-month formulation of an HIV drug has found that drug levels were maintained at a level that should in theory be high enough to protect recipients against infection, and that the drug has so far produced very few side effects. The research was presented Read More >>

via AidsMap.com, by Gus Cairnes Adherence makes all the difference to the efficacy of pre-exposure prophylaxis (PrEP), the 19th Conference on Retroviruses and Opportunistic Infections (CROI) heard today. Further data were presented from two trials of PrEP (giving anti-HIV drugs to HIV-negative people to prevent infection), which announced dramatically different results last year. In April 2011, the Read More >>

via AidsMap.com, by Gus Cairns Further testing of drug levels in the blood and immune cells of gay men participating in the iPrEx trial of tenofovir/FTC (Truvada) pre-exposure prophylaxis (PrEP) has found that HIV infection in men assigned to Truvada was associated with a lapse in taking the drug after initially adhering reasonably well, rather than never Read More >>

via AidsMap.com, by Gus Cairns A gel containing 1% tenofovir formulated specifically for rectal use was much better tolerated than gels used in previous rectal microbicide trials when used in a safety study in 65 HIV-negative men and women, the 19th Conference on Retroviruses and Opportunistic Infections (CROI) heard yesterday. The gel was also compared with other Read More >>

via MedPage Today, by Michael Smith Giving anti-retroviral drugs to HIV-negative people can reduce their risk of acquiring the virus from an HIV-positive partner, a researcher said here. In a large randomized controlled trial in Africa, this type of pre-exposure prophylaxis, or PrEP, cut the risk of infection by up to 75% compared with placebo, according to Read More >>

via Aidsmap, by Gus Cairns Moupali Das of the San Francisco Department of Public Health presented evidence to show that the city’s intensive testing and treatment policy was beginning to result in a declining HIV infection rate there. Similar evidence was presented from the province of British Columbia in Canada. The evidence presented still leaves some questions Read More >>